Information Provided By:
Fly News Breaks for March 6, 2015
OSIR
Mar 6, 2015 | 08:21 EDT
Brean Capital views the weakness in Osiris as a buying opportunity, saying the fundamental story has not changed despite inline Q4 results. The firm cited the company's transition from a stem cell to wound care company, sales force expansion, and reimbursement wins which are not priced in as of yet. Brean Capital reiterated its Buy rating and $19 price target on Osiris shares.
News For OSIR From the Last 2 Days
There are no results for your query OSIR
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.